GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
GO:0044282 | Colorectum | AD | small molecule catabolic process | 118/3918 | 376/18723 | 1.05e-06 | 3.55e-05 | 118 |
GO:0019079 | Colorectum | AD | viral genome replication | 51/3918 | 131/18723 | 1.83e-06 | 5.51e-05 | 51 |
GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
GO:1903900 | Colorectum | AD | regulation of viral life cycle | 51/3918 | 148/18723 | 9.01e-05 | 1.38e-03 | 51 |
GO:0045069 | Colorectum | AD | regulation of viral genome replication | 32/3918 | 85/18723 | 2.97e-04 | 3.60e-03 | 32 |
GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
GO:00190581 | Colorectum | SER | viral life cycle | 87/2897 | 317/18723 | 2.82e-08 | 1.94e-06 | 87 |
GO:00442821 | Colorectum | SER | small molecule catabolic process | 87/2897 | 376/18723 | 5.31e-05 | 1.27e-03 | 87 |
GO:00190791 | Colorectum | SER | viral genome replication | 37/2897 | 131/18723 | 1.36e-04 | 2.72e-03 | 37 |
GO:00442701 | Colorectum | SER | cellular nitrogen compound catabolic process | 99/2897 | 451/18723 | 1.46e-04 | 2.86e-03 | 99 |
GO:00467001 | Colorectum | SER | heterocycle catabolic process | 97/2897 | 445/18723 | 2.20e-04 | 3.89e-03 | 97 |
GO:00507921 | Colorectum | SER | regulation of viral process | 43/2897 | 164/18723 | 2.57e-04 | 4.31e-03 | 43 |
GO:19013611 | Colorectum | SER | organic cyclic compound catabolic process | 104/2897 | 495/18723 | 5.46e-04 | 7.63e-03 | 104 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0541714 | Liver | NAFLD | Lipid and atherosclerosis | 42/1043 | 215/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 42 |
hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0541715 | Liver | NAFLD | Lipid and atherosclerosis | 42/1043 | 215/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 42 |
hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541722 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541732 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa0541712 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa04975 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
hsa0541713 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa049751 | Stomach | GC | Fat digestion and absorption | 14/708 | 43/8465 | 5.71e-06 | 8.30e-05 | 5.84e-05 | 14 |
hsa0541710 | Stomach | SIM | Lipid and atherosclerosis | 34/465 | 215/8465 | 1.80e-08 | 4.20e-07 | 3.37e-07 | 34 |
hsa049752 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
hsa04979 | Stomach | SIM | Cholesterol metabolism | 8/465 | 51/8465 | 6.17e-03 | 3.83e-02 | 3.08e-02 | 8 |
hsa0541711 | Stomach | SIM | Lipid and atherosclerosis | 34/465 | 215/8465 | 1.80e-08 | 4.20e-07 | 3.37e-07 | 34 |
hsa049753 | Stomach | SIM | Fat digestion and absorption | 12/465 | 43/8465 | 2.11e-06 | 3.05e-05 | 2.45e-05 | 12 |
hsa049791 | Stomach | SIM | Cholesterol metabolism | 8/465 | 51/8465 | 6.17e-03 | 3.83e-02 | 3.08e-02 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APOB | SNV | Missense_Mutation | novel | c.6441N>C | p.Lys2147Asn | p.K2147N | P04114 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APOB | SNV | Missense_Mutation | | c.4027N>A | p.Pro1343Thr | p.P1343T | P04114 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APOB | SNV | Missense_Mutation | novel | c.9304N>G | p.Phe3102Val | p.F3102V | P04114 | protein_coding | tolerated(0.09) | probably_damaging(0.995) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
APOB | SNV | Missense_Mutation | | c.7897N>C | p.Phe2633Leu | p.F2633L | P04114 | protein_coding | tolerated(0.66) | benign(0.231) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD |
APOB | SNV | Missense_Mutation | | c.5870N>T | p.Arg1957Met | p.R1957M | P04114 | protein_coding | tolerated(0.06) | possibly_damaging(0.707) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD |
APOB | SNV | Missense_Mutation | | c.13538N>G | p.Phe4513Cys | p.F4513C | P04114 | protein_coding | deleterious(0.03) | benign(0.153) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
APOB | SNV | Missense_Mutation | rs377125320 | c.12698N>T | p.Ser4233Leu | p.S4233L | P04114 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
APOB | SNV | Missense_Mutation | | c.10775N>T | p.Ser3592Phe | p.S3592F | P04114 | protein_coding | tolerated(0.41) | benign(0.085) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
APOB | SNV | Missense_Mutation | | c.10023N>A | p.Phe3341Leu | p.F3341L | P04114 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
APOB | SNV | Missense_Mutation | | c.9752N>G | p.Tyr3251Cys | p.Y3251C | P04114 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | ETHANOL | ALCOHOL | 8576634 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LOVASTATIN | LOVASTATIN | 2351867,7662319,1588827 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | LIGNAN | | 15671223 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | TKM-APOB | | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | QUERCETIN | QUERCETIN | 16149735 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | lomitapide | LOMITAPIDE | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | EPIGALLOCATECHIN GALLATE | | 11936850 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PRAVASTATIN | PRAVASTATIN | 8312689 |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | warfarin | WARFARIN | |
338 | APOB | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | DEXAMETHASONE | DEXAMETHASONE | 7670964 |